Principal Financial Group Inc. Grows Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Principal Financial Group Inc. grew its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 3.9% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,745,818 shares of the specialty pharmaceutical company’s stock after purchasing an additional 64,958 shares during the quarter. Principal Financial Group Inc. owned about 5.41% of Collegium Pharmaceutical worth $67,459,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the business. Pacer Advisors Inc. lifted its holdings in Collegium Pharmaceutical by 31.8% during the 2nd quarter. Pacer Advisors Inc. now owns 3,408,369 shares of the specialty pharmaceutical company’s stock worth $109,749,000 after purchasing an additional 821,541 shares in the last quarter. Rubric Capital Management LP lifted its holdings in shares of Collegium Pharmaceutical by 27.2% in the second quarter. Rubric Capital Management LP now owns 2,333,500 shares of the specialty pharmaceutical company’s stock worth $75,139,000 after buying an additional 499,473 shares in the last quarter. Victory Capital Management Inc. lifted its holdings in shares of Collegium Pharmaceutical by 43.6% in the third quarter. Victory Capital Management Inc. now owns 710,688 shares of the specialty pharmaceutical company’s stock worth $27,461,000 after buying an additional 215,874 shares in the last quarter. Emerald Advisers LLC boosted its position in shares of Collegium Pharmaceutical by 27.2% in the third quarter. Emerald Advisers LLC now owns 827,302 shares of the specialty pharmaceutical company’s stock valued at $31,967,000 after acquiring an additional 177,129 shares during the period. Finally, Emerald Mutual Fund Advisers Trust grew its stake in Collegium Pharmaceutical by 24.9% during the third quarter. Emerald Mutual Fund Advisers Trust now owns 662,291 shares of the specialty pharmaceutical company’s stock valued at $25,591,000 after acquiring an additional 131,835 shares in the last quarter.

Wall Street Analyst Weigh In

COLL has been the subject of several analyst reports. HC Wainwright raised their price target on shares of Collegium Pharmaceutical from $47.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, September 5th. Piper Sandler restated a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Finally, StockNews.com lowered Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, October 23rd. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $42.60.

Collegium Pharmaceutical Stock Down 2.4 %

Shares of NASDAQ:COLL opened at $29.70 on Friday. The firm has a market capitalization of $957.83 million, a PE ratio of 12.80 and a beta of 0.80. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a 52-week low of $28.97 and a 52-week high of $42.29. The firm has a fifty day moving average of $32.48 and a 200 day moving average of $34.30.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.